11. The method of any one of claims 8-10, further comprising comparing the amount of IL-10 produced or the percentage of cells capable of producing IL-10 to a control having normal B10 cell function and determining if the B10 cell function is normal or abnormal in the subject.
12. The method of any one of claims 8-11, further comprising diagnosing the subject as having normal, deficient or over-active B10 cells.
13. The method of any one of claims 11-12, further comprising using the comparison to diagnose whether the subject has a disease or condition affecting B10 cell function, wherein the disease or condition is an autoimmune disease, graft versus host disease, transplant rejection, anti-drug antibodies, or an inflammatory disorder.
14. The method of any one of the preceding claims, wherein the B cells are harvested from the blood, spleen, peritoneal cavity, lymph nodes, bone marrow, site of autoimmune disease, site of inflammation or tissue undergoing transplant rejection of the subject.
15. The method of any one of the preceding claims, wherein the B cells are isolated by removal of non-B cells, or selection for cell surface IgM, IgD, IgG, IgA, IgE, CD19, CD20, CD21, CD22, CD24, CD40, CD72, CD79a, CD79b, CD1d, CD5, CD9, CD10, CD23, CD27, CD38, CD48, CD80, CD86, CD138, CD148 or combinations thereof prior to use in the method.
16. The method of any one of claims 2-15, wherein the CD40 agonist is selected from the group consisting of CD154, a fragment of CD154, and an antibody, aptamer or polypeptide, or fragment thereof reactive with CD40.
17. The method of any one of claims 2-16, wherein the B cell survival promoter is selected from the group consisting of at least one of feeder cells, BAFF (BLyS), BAFF fragments, APRIL, CD22 ligand, CD22 monoclonal antibody, and fragments thereof.
18. The method of any one of claims 2-17, wherein the feeder cells are fibroblast, endothelial cells, epithelial cells, keratinocytes, melanocytes, or other mesenchymal or stromal cells.
19. The method of any one of claims 3-18, wherein the B cells are contacted with IL-4 for three to ten days.
20. The method of any one of the preceding claims, wherein the B cells are contacted with IL-21 for four to eight days.

21. The method of any one of claims 1-7 or 14-20, wherein the B10 cells are producing IL-10, or are isolated based on differential expression of cell surface molecules including IgM, IgD, IgG, IgA, IgE, CD19, CD20, CD21, CD22, CD24, CD40, CD72, CD79a, CD79b, CD1d, CD5, CD9, CD10, CD1d, CD23, CD27, CD38, CD48, CD80, CD86, CD138, CD148 or combinations thereof.
22. The method of any one of claims 1-7 or 14-21, wherein the isolated B10 cells are more than 50% B10 cells capable of producing IL-10.
23. The method of any one of the preceding claims, wherein the B cells and the B10 cells are polyclonal.